Phathom Pharmaceuticals Overview

  • Founded
  • 2018

Founded
  • Status
  • Public

  • Employees
  • 97

Employees
  • Stock Symbol
  • PHAT

Stock Symbol
  • Share Price
  • $12.00

  • (As of Thursday Closing)

Phathom Pharmaceuticals General Information

Description

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
  • 100 Campus Drive
  • Suite 102
  • Florham Park, NJ 07932
  • United States
+1 (877) 000-0000

Phathom Pharmaceuticals Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Phathom Pharmaceuticals Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$12.00 $11.72 $6.09 - $19.95 $499M 41.6M 258K -$4.67

Phathom Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 321,121 487,879 758,010 807,112
Revenue 0 0 0 0
EBITDA (158,288) (136,615) (125,255) (252,035)
Net Income (178,502) (143,883) (129,068) (255,131)
Total Assets 201,931 189,431 295,111 257,178
Total Debt 95,810 91,341 49,018 23,573
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Phathom Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Phathom Pharmaceuticals‘s full profile, request access.

Request a free trial

Phathom Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing an
Biotechnology
Florham Park, NJ
97 As of 2022
00000
000000000 00000

000000

elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
0000000000000
Boston, MA
000 As of 0000
00000
000000 - 000 00000

000000

a commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit e
0000 000000000
Fremont, CA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Phathom Pharmaceuticals Competitors (34)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rhythm Pharmaceuticals Formerly VC-backed Boston, MA 000 00000 000000 - 000 00000
0000000 Formerly VC-backed Fremont, CA 000 00000 000000 - 000 00000
000000000 00000000 Formerly VC-backed San Diego, CA 000 00000 000000000 00000
000000000000000 Formerly VC-backed Blacksburg, VA 0 00000000000
0000000 Formerly PE-Backed Boston, MA 000 00000 000000&0 00000
You’re viewing 5 of 34 competitors. Get the full list »

Phathom Pharmaceuticals Executive Team (11)

Name Title Board Seat Contact Info
Terrie Curran President, Chief Executive Officer & Board Member
Azmi Nabulsi MD Founder & Chief Operating Officer, Operations
Joseph Hand JD Chief Administrative Officer
Tom Harris Corporate Development Officer
Martin Gilligan Chief Commercial Officer
You’re viewing 5 of 11 executive team members. Get the full list »

Phathom Pharmaceuticals Board Members (11)

Name Representing Role Since
David Socks Self Founder & Board Member 000 0000
Frank Karbe Self Board Member 000 0000
Heidi Kunz Phathom Pharmaceuticals Board Member 000 0000
Mark Stenhouse Self Board Member 000 0000
Michael Cola Phathom Pharmaceuticals Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Phathom Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Phathom Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Phathom Pharmaceuticals‘s full profile, request access.

Request a free trial

Phathom Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated December, 10, 2022

33.82 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.0

Percentile

Pharmaceuticals

Subindustry

00 of 473

Rank

00.00

Percentile

To view Phathom Pharmaceuticals’s complete esg history, request access »